GoodRx Holdings, Inc. operates a digital healthcare platform focused on prescription and medication savings in the United States. Company news commonly covers prescription transaction revenue, retail pharmacy trends, negotiated discount pricing, PBM relationships, and the expansion of Pharma Direct manufacturer programs that connect branded drug discounts to consumers at the pharmacy counter.
GoodRx updates also include self-pay pricing arrangements for GLP-1 and other branded medications, subscription health services such as condition-specific programs, earnings releases, business outlook commentary, and partnerships with pharmaceutical manufacturers, pharmacies, payers, and healthcare professionals.
GoodRx (NASDAQ: GDRX), the leading prescription savings platform in the U.S., has announced a partnership with retail pharmacies to offer a pay-over-time option for select medications directly on the GoodRx platform. The program, launching with partner pharmacies including Hy-Vee, will allow approved users to select an Affirm payment plan when purchasing their prescriptions.
The new feature aims to provide consumers with financial flexibility and control, potentially helping them reach deductibles or access medications more easily. The process will be integrated into the GoodRx platform, allowing users to validate prescriptions, check inventory, and choose payment options before picking up their medications at local pharmacies.
This initiative is part of GoodRx's broader e-commerce strategy to simplify the prescription process for patients and retail pharmacies. The program is expected to roll out in the coming months, with the goal of improving medication adherence and removing healthcare barriers.
GoodRx Holdings, Inc. (Nasdaq: GDRX), the leading prescription savings platform in the U.S., has announced the date for its third quarter 2024 earnings release and conference call. The company will release its financial results on Thursday, November 7, 2024, before U.S. markets open. GoodRx management will hold a conference call and webcast at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on the same day to discuss the results and the Company's business outlook.
Interested parties can pre-register for the conference call using a provided link, which will give them dial-in details and a unique passcode. The call will also be webcast live on the Company's investor relations website. Accompanying materials will be posted prior to the conference call. An archived version of the webcast will be available on the investor relations website for at least 30 days after the live call.
GoodRx (Nasdaq: GDRX) has announced it is offering the lowest discounted cash price for neffy®, the first needle-free treatment for Type I allergic reactions, including anaphylaxis. Consumers can access a pack of two single-use neffy devices for $199 at over 70,000 pharmacies nationwide exclusively through GoodRx. neffy, approved by the FDA in August, delivers epinephrine nasally, providing an innovative alternative to auto-injectors.
This partnership with ARS Pharmaceuticals aims to enhance accessibility and affordability for millions of Americans affected by allergies. GoodRx's collaboration with nearly 150 brands across the healthcare industry demonstrates its commitment to providing cost-effective treatments and patient support programs.
GoodRx Holdings, Inc. (Nasdaq: GDRX), the leading prescription savings platform in the U.S., has announced its participation in two upcoming investor conferences. The company's executives will engage in fireside chats at:
- The Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 5, 2024, at 7:45 a.m. ET
- The Wells Fargo 2024 Healthcare Conference in Boston, MA on September 6, 2024, at 8:00 a.m. ET
Both events will be livestreamed on GoodRx's Investor Relations website, with archived recordings available for at least 30 days after each conference.
GoodRx Holdings, Inc. (Nasdaq: GDRX) reported its Q2 2024 financial results, showing positive growth and profitability. Key highlights include:
- Revenue increased 6% to $200.6 million
- Net income of $6.7 million, with a 3.3% margin
- Adjusted EBITDA of $65.4 million, with a 32.6% margin
- Over 7 million consumers of prescription-related offerings
The company's guidance for Q3 2024 projects revenue between $193-197 million and an Adjusted EBITDA Margin of about 32%. For the full year 2024, GoodRx expects revenue at the lower end of $800-810 million, with Adjusted EBITDA over $255 million, up 17% from 2023.
Boehringer Ingelheim and GoodRx (Nasdaq: GDRX) have announced an exclusive patient affordability initiative for Adalimumab-adbm, Boehringer's biosimilar to Humira®. This FDA-approved interchangeable biosimilar will be available at a low cash price exclusively on the GoodRx platform, representing a significant step in addressing access and affordability for patients with certain autoimmune conditions.
Key points:
- The initiative offers both high-concentration and low-concentration citrate-free formulations at $550 per two-pack, a 92% discount from Humira's list price
- Available at over 70,000 retail pharmacies nationwide
- Accessible to anyone with a valid prescription, regardless of insurance status
- Aims to speed up time to therapy for patients using biologic drugs
GoodRx Holdings, the leading prescription savings platform in the U.S., announced the release date of its second quarter 2024 financial results. The report will be made public on Thursday, August 8, 2024, before the U.S. markets open.
On the same day, at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time), the company will hold a conference call and webcast to discuss the results and business outlook. Interested parties can pre-register for the call to receive dial-in details and a unique passcode. The live webcast and accompanying materials will be available on the company's investor relations website. An archived version of the webcast will be accessible approximately one hour after the live event and will remain available for at least 30 days.
GoodRx Holdings announced the addition of former Genentech CEO, Ian T. Clark, to its Board of Directors. Clark brings over 35 years of experience in pharmaceuticals and healthcare, having held leadership roles at Genentech, Novartis, Sanofi, Ivax Pharmaceuticals, and G.D. Searle. He currently serves on the boards of multiple biopharmaceutical and biotechnology companies including Kyverna Therapeutics, Olema Pharmaceuticals, Takeda Pharmaceuticals, Guardant Health, and Corvus Pharmaceuticals. GoodRx anticipates that Clark's deep industry knowledge will enhance their efforts to provide affordable prescription prices and strengthen their board's expertise in the healthcare sector. Clark will join the Nominating and Corporate Governance Committee and chair the newly established Innovation Committee.
GoodRx (Nasdaq: GDRX) has launched a new 'Prescription Cost Tracker' aimed at shedding light on out-of-pocket medication costs in the U.S. as of 2024. The tool will track trends in prescription spending, highlighting key factors such as high medication costs, reduced insurance coverage, and increased friction in the system.
Key findings include that Americans have spent $21 billion out-of-pocket on prescriptions in 2024, averaging $16.26 per prescription. Additionally, 37% of prescription medication list prices have increased since 2014. Reduced insurance coverage is also a significant issue, with only 54% of medications covered by insurance and 50% of those covered by Medicare having restrictions. Increased friction is seen in challenges like 41 million Americans lacking proper access to a pharmacy.
GoodRx aims to use the data to fight for lower prescription costs and provide greater price transparency for consumers.
GoodRx (Nasdaq: GDRX) has appointed Simon Patterson to its Board of Directors. Patterson, who leads EMEA operations for Silver Lake, a technology investment firm, brings extensive experience in tech, strategy, and management. He has held board positions at companies like Dell Technologies and Skype. Patterson's expertise is expected to assist GoodRx in scaling its business and making prescription medications more affordable. He will also join the Board's Nominating and Corporate Governance Committee.